Full history for every metric is available with a Kvantra account
Constellation Pharmaceuticals, Inc. (CNST)
Key financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -125 | -139 | |||||
| Net profit | $m | - | -35 | -35 | -60 | -86 | -126 | -141 |
| EPS reported | $ | -2.65 | -3.04 | |||||
| Operating cashflow per share | $ | -2.34 | -2.34 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -2.36 | -2.36 | |||||
| Free cash flow | $m | -112 | -127 | |||||
| Net debt | $m | -417 | -379 | |||||
| Book value equity | $m | 411 | 377 | |||||
| Book value per share | $ | 8.61 | 7.89 | |||||
| Number of shares | m | 47.69 | 47.84 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.34 | 4.31 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -12.22 | -12.85 | |||||
| EV/EBITDA LTM | x | -9.88 | -9.02 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -9.20% | -7.80% | |||||
| FCF Yield | % | -8.18% | -7.78% | |||||
| Quality | ||||||||
| ROE | % | -30.76% | -33.77% | |||||
| ROIC | % | -30.09% | -30.09% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -26.59 | -37.60 | |||||
| Net Debt/EBITDA | x | 1.30 | 1.30 | |||||
| EBIT/Net interest | x | -43.62 | -43.62 | |||||
| Net debt/market cap | % | -30.38% | -23.29% | |||||
| Net debt/Equity | x | -1.02 | -1.00 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Constellation Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity, dedicated to identifying and advancing novel therapeutic solutions. Its core mission is to address critical unmet medical requirements for patients battling cancers characterized by aberrant gene expression or drug resistance. The company's pipeline features several key candidates: CPI-0610 is undergoing Phase II clinical assessment for myelofibrosis, administered in combination with ruxolitinib. Another significant compound, CPI-1205, is currently in Phase Ib/II clinical trials, targeting metastatic castration-resistant prostate cancer when used alongside androgen receptor signaling inhibitors. Beyond these, Constellation is also progressing CPI-0209 through the Phase I dose-escalation segment of its Phase I/II clinical trial for solid tumors. Established in 2008, the firm was formerly known as Epigenetix, Inc. before rebranding in March of that year to its present name. Constellation Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Constellation Pharmaceuticals, Inc. (CNST)
Constellation Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity, dedicated to identifying and advancing novel therapeutic solutions. Its core mission is to address critical unmet medical requirements for patients battling cancers characterized by aberrant gene expression or drug resistance. The company's pipeline features several key candidates: CPI-0610 is undergoing Phase II clinical assessment for myelofibrosis, administered in combination with ruxolitinib. Another significant compound, CPI-1205, is currently in Phase Ib/II clinical trials, targeting metastatic castration-resistant prostate cancer when used alongside androgen receptor signaling inhibitors. Beyond these, Constellation is also progressing CPI-0209 through the Phase I dose-escalation segment of its Phase I/II clinical trial for solid tumors. Established in 2008, the firm was formerly known as Epigenetix, Inc. before rebranding in March of that year to its present name. Constellation Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free